Publication Date
Fall 9-26-2022
Project Category
Health Research
Faculty Mentor
Susan Miranda, PhD
Document Type
Paper
Abstract
Osteosarcoma is the most common primary bone malignancy. There is currently no targeted therapy, so standard treatment involves surgical resection along with chemotherapy. There is a large subset of osteosarcoma that has a high expression of WNT5B, which is linked to a worse overall survival probability. The WNT5B pathway in osteosarcoma is not known, so we wanted to find out what receptors it signals through. We came up with two candidates, ROR1 and FZD2, then tested our hypothesis using immunohistochemistry. We first optimized the antigen retrieval step and ROR1 primary antibody for our immunohistochemistry protocol then proceeded to test our hypothesis. We found that when WNT5B is present in the tumor, ROR1 and FZD2 are also present, likewise, when WNT5B is absent ROR1 and FZD2 are also absent. We also noticed that these proteins are all confined to the tumor itself, not the stroma. Lastly, we saw that WNT5B, ROR1 and FZD2 appear to be in the same locations in each sample, suggesting a potential signaling relationship. We hope to one day use these receptors as druggable targets to disrupt the WNT5B pathway in patients that have osteosarcoma with WNT5B overexpression.
Recommended Citation
Wright, Alec J.; Miranda, Susan PhD; and Miranda-Carboni, Gustavo PhD , "The Co-expression of ROR1 and FZD2 in WNT5B Signaling in Osteosarcoma" (2022). Longitudinal Scholar's Project. Paper 25. http://dx.doi.org/10.21007/com.lsp.2024.0022.
https://dc.uthsc.edu/lsp/25
Included in
Amino Acids, Peptides, and Proteins Commons, Medical Education Commons, Neoplasms Commons, Oncology Commons